Table 3.
Number (frequency) of participants that reported side effects immediately after the testing protocol (side effects questionnaire (QUEST) + 0 hour) and 24 hours later (QUEST + 24 hours).
| Side Effects | Occurrence of Side Effects in Particular Groups | |||||
|---|---|---|---|---|---|---|
| PLAC | CAF-9 | CAF-11 | ||||
| +0 h | +24 h | +0 h | +24 h | +0 h | +24 h | |
| Muscle soreness | 0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
| Increased urine output | 1 (6%) |
1 (6%) |
10 (63%) |
9 (57%) |
10 (63%) |
10 (63%) |
| Tachycardia and heart palpitations | 3 (19%) |
1 (6%) |
12 (76%) |
11 (69%) |
15 (92%) |
13 (81%) |
| Anxiety or nervousness | 1 (6%) |
2 (13%) |
11 (69%) |
4 (25%) |
14 (88%) |
13 (81%) |
| Headache | 2 (13%) |
1 (6%) |
3(19%) | 6 (37%) |
8(50%) | 8 (50%) |
| Gastrointestinal problems | 0 (0%) |
1 (6%) |
6 (38%) |
10(63%) | 6 (38%) |
13 (81%) |
| Perception of performance improvement | 2 (13%) |
0 (0%) |
14 (88%) |
0 (0%) |
6 (38%) |
0 (0%) |
| Increased vigor/activeness | 2 (13%) |
1 (6%) |
13(81%) | 8 (50%) |
6 (38%) |
6 (38%) |
| Insomnia | 0 (0%) |
0 (0%) |
0 (0%) |
4 (25%) |
0 (0%) |
6 (38%) |
Data are presented as the number of participants (frequency) that responded affirmatively to the existence of a side effect.